57
4-Factor PCC Activated PCC
Prothrombin complex concentrate: coagulation
factors II, VII, IX, and X
Anticoagulation proteins C and S
Nonactivated factors II, IX, and X
Activated VII
e urgent reversal for acute major bleeding or
need for an urgent surgery/invasive procedure in
patients receiving vitamin K antagonists
Control and prevention of bleeding
episodes, perioperative management,
prophylaxis to prevent or reduce
bleeding frequency in hemophilia A
and B patients
Reversal of factor Xa inhibitors in patients
requiring urgent procedure or with life-
threatening bleeding
Dabigatran- associated life-
threatening bleeding
Warfarin reversal based on pretreatment INR
(units of factor IX):
1. INR 2 to <4: 25 units/kg (up to 2500 units)
2. INR 4 to 6: 35 units/kg (up to 3500 units)
3. INR 6<: 50 units/kg (up to 5000 units)
Oral factor Xa inhibitors: 2000 units once or 25
to 50 units/kg
Dabigatran- associated life-
threatening bleeding : 50 units/kg
once
Within 10 min Within 30 min
8 h 12 h
Warfarin reversal: Repeat INR within 30 min
aer the administration
N/A
May not be indicated for patients with
thromboembolic events in the prior 3 mon
It includes heparin
Administer intravenous vitamin K 10 mg over
10–20 min in addition to 4-factor PCC
It does not include heparin
Coagulation parameters do not
correlate with the drug's efficacy
Not effective to reverse factor Xa
inhibitors
